- Conditions
- Tumors, Lymphoma, Multiple Myeloma
- Interventions
- ridaforolimus
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 817–840
of 5,456
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma, Synovial Sarcoma
- Interventions
- Lymphodepletion, TCR-T cells (MDG1015)
- Drug · Biological
- Lead sponsor
- Medigene AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Solid Tumor
- Interventions
- LY3415244
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer), Advanced Solid Tumors
- Interventions
- ALTA3263, cetuximab, mFOLFOX6, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin, mFOLFIRINOX, GnP, Midazolam
- Drug
- Lead sponsor
- Alterome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 12
- States / cities
- Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more
- Conditions
- Solid Tumor
- Interventions
- Cabozantinib, 13-cis-retinoic acid
- Drug
- Lead sponsor
- Peter Zage
- Other
- Eligibility
- 2 Years to 26 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- San Diego, California • Atlanta, Georgia
- Conditions
- Solid Tumor, Adult, Homologous Recombination Deficiency
- Interventions
- Niraparib, Carboplatin
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Hackensack, New Jersey + 1 more
- Conditions
- Solid Tumor
- Interventions
- JBZ-001
- Drug
- Lead sponsor
- Jabez Bioscience, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • West Valley City, Utah
- Conditions
- Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- ketamine/amitriptyline NP-H cream, placebo
- Drug · Other
- Lead sponsor
- Gary Morrow
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 17
- States / cities
- Honolulu, Hawaii • Chicago, Illinois • Decatur, Illinois + 14 more
- Conditions
- Neoplasms
- Interventions
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
- Drug
- Lead sponsor
- Vincerx Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 13
- States / cities
- Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
- Conditions
- Endometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer
- Interventions
- COM701 in combination with BMS-986207 and nivolumab.
- Drug
- Lead sponsor
- Compugen Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 6 more
- Conditions
- Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- lidocaine, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 159
- States / cities
- Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 95 more
- Conditions
- Neoplasms, Hematologic Neoplasms, Healthy Volunteers
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 6,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin Lymphoma, Childhood Acute Myeloid Leukemia, Childhood Burkitt Lymphoma, Childhood Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Recurrent Childhood Acute Lymphoblastic Leukemia
- Interventions
- Informational Intervention, Interview, Medical Chart Review, Questionnaire Administration
- Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 20 Years
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 31
- States / cities
- Oakland, California • Wilmington, Delaware • Fort Myers, Florida + 23 more
- Conditions
- Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastrointestinal Stromal Tumour, Head and Neck Cancer, Liver Cancer, Melanoma, Mouth Cancer, Nasopharangeal Cancer, Neuroendocrine, Gastrointestinal Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcoma, Small Cell Lung Cancer, Testicular Cancer, Throat Cancer, Thyroid Cancer, Urethral Cancer, Vaginal Cancer, Vulvar Cancer
- Interventions
- Trastuzumab deruxtecan
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 15 more
- Conditions
- Triple Negative Metastatic Breast Cancer, BRCA-mutated Solid Tumor
- Interventions
- BMN-673, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Pamela Munster
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Solid Tumor, Solid Tumor, Adult
- Interventions
- Sargramostim, Ipilimumab-containing therapy
- Biological
- Lead sponsor
- Partner Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Lexington, Massachusetts
- Conditions
- Advanced Solid Tumor
- Interventions
- Utidelone Capsule
- Drug
- Lead sponsor
- Biostar Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Solid Tumors
- Interventions
- LY573636, Pemetrexed
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- irinotecan hydrochloride, temozolomide, vincristine sulfate
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Orange, California • Stanford, California + 13 more
- Conditions
- Parent-Child Relations, Cancer, Survivorship, Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Parent-Child Relation, Parenting
- Interventions
- Group 1: Educational counseling intervention, Group II Active Comparator
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 23 Years to 68 Years
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Seattle, Washington
- Conditions
- Immune-related Adverse Events, Advanced Solid Tumor
- Interventions
- Rituximab, Tocilizumab
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • New York, New York
- Conditions
- Solid Tumors, NHL
- Interventions
- KPT-9274, Niacin ER, Nivolumab
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
- Conditions
- Solid and Hematological Malignancies, Autoimmune Diseases
- Interventions
- Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, Anitocabtagene autleucel, KITE-753, KITE-197, KITE-363, INT2104, KITE-512, SPRX001, SPRX002, ARC-T Cells
- Biological
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2040
- U.S. locations
- 49
- States / cities
- Gilbert, Arizona • Duarte, California • La Jolla, California + 38 more
- Conditions
- Advanced Solid Tumor
- Interventions
- Ramucirumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 4
- States / cities
- Fayetteville, Arkansas • Omaha, Nebraska • Charlotte, North Carolina + 1 more